Aurora kinase inhibitors - Rising stars in cancer therapeutics?

Altaf A. Dar, Laura W. Goff, Shahana Majid, Jordan Berlin, Wael El-Rifai

Research output: Contribution to journalReview article

189 Citations (Scopus)

Abstract

Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.

Original languageEnglish (US)
Pages (from-to)268-278
Number of pages11
JournalMolecular Cancer Therapeutics
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Aurora Kinases
Neoplasms
Therapeutics
Aurora Kinase B
Aurora Kinase A
Poisons
Protein-Serine-Threonine Kinases
Aneuploidy
Hematologic Neoplasms
Mitosis
Epigenomics
Clinical Trials
Genome
Radiation
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aurora kinase inhibitors - Rising stars in cancer therapeutics? / Dar, Altaf A.; Goff, Laura W.; Majid, Shahana; Berlin, Jordan; El-Rifai, Wael.

In: Molecular Cancer Therapeutics, Vol. 9, No. 2, 01.02.2010, p. 268-278.

Research output: Contribution to journalReview article

Dar, Altaf A. ; Goff, Laura W. ; Majid, Shahana ; Berlin, Jordan ; El-Rifai, Wael. / Aurora kinase inhibitors - Rising stars in cancer therapeutics?. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 2. pp. 268-278.
@article{1bccd3a136d0407b838862a6059322f0,
title = "Aurora kinase inhibitors - Rising stars in cancer therapeutics?",
abstract = "Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.",
author = "Dar, {Altaf A.} and Goff, {Laura W.} and Shahana Majid and Jordan Berlin and Wael El-Rifai",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0765",
language = "English (US)",
volume = "9",
pages = "268--278",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Aurora kinase inhibitors - Rising stars in cancer therapeutics?

AU - Dar, Altaf A.

AU - Goff, Laura W.

AU - Majid, Shahana

AU - Berlin, Jordan

AU - El-Rifai, Wael

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.

AB - Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The molecular analysis of the cancer genomes have shown a remarkable complexity and pointed to key genomic and epigenomic alterations in cancer. These discoveries are paving the way for targeted therapy approaches. However, although there are a large number of potential targets, only a few can regulate key cellular functions and intersect multiple signaling networks. The Aurora kinase family members (A, B, and C) are a collection of highly related and conserved serine-threonine kinases that fulfill these criteria, being key regulators of mitosis and multiple signaling pathways. Alterations in Aurora kinase signaling are associated with mitotic errors and have been closely linked to chromosomal aneuploidy in cancer cells. Several studies have shown amplification and/or overexpression of Aurora kinase A and B in hematologic malignancies and solid tumors. Over the past several years, Aurora kinases have become attractive targets. Several ongoing clinical trials and bench-based research are assessing the unique therapeutic potential of Aurora-based targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=76649120544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649120544&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0765

DO - 10.1158/1535-7163.MCT-09-0765

M3 - Review article

C2 - 20124450

AN - SCOPUS:76649120544

VL - 9

SP - 268

EP - 278

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -